The U.S. Supreme Court heard arguments in a patent case that could reshape how generic drugmakers market copycat products approved under the Hatch‑Waxman Act, with major implications for innovation and drug affordability. The dispute stems from claims by Amarin Pharma that Hikma induced infringement of patents covering a cardiovascular use of Amarin’s heart drug, despite selling its generic version under a “skinny label” limited to non‑patented indications. A federal appeals court in 2024 held those allegations sufficient to state a claim for induced infringement.
Finnegan attorney Charles Collins‑Chase suggested that a ruling in favor of Hikma Pharmaceuticals could limit patent enforcement by brand‑name drugmakers. “A ruling for Hikma could keep brand‑name drugmakers’ patent infringement cases from getting off the ground, even when the complaint relies on evidence like marketing statements to doctors,” Charles said.
He added that such an outcome “could have a chilling effect on innovation, leaving brand‑name manufacturers unable to protect new, patented uses and recover their investments in clinical studies.”
Industry groups are sharply divided, with brand‑name manufacturers urging the Court not to insulate generics from inducement liability, while generic advocates argue that expanding such liability could deter market entry and threaten drug affordability.
